Cancer makes new friends with old tricks

Slides:



Advertisements
Similar presentations
Immune dysfunction & its consequences
Advertisements

IMMUNOSUPPRESSIVE NETWORKS IN THE TUMOUR ENVIRONMENT AND THEIR THERAPEUTIC RELEVANCE 高丰光 Weiping Zou NATURE REVIEWS | CANCER VOLUME 5 | APRIL 2005 | 263.
Cellules myeloides suppressives
Host Defense Against Tumors (Tumor Immunity)
A Role for Immature Myeloid Cells in Immune Senescence Elena Y. Enioutina Diana Bareyanand Raymond A. Daynes.
Laboratory of cellular immunology
Snail-overexpressing cancer cells modulates tumor-associated macrophages through promoting M2 polarization and suppressing inflammasome activation Speaker:
Immunotherapy of hepatocellular carcinoma
The function and mechanism of mast cell in anti-colon cancer immunity
Figure 1 Key elements of cancer-related inflammation
Impaired Toll-like receptor 8–mediated IL-6 and TNF-α production in antigen-presenting cells from patients with X-linked agammaglobulinemia by Klára Sochorová,
by Venetia Bigley, Laura E. Spence, and Matthew Collin
When monocyte life hangs by a thread
Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis
BTK inhibition in myeloma: targeting the seed and the soil
Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment by Francis Mussai, Carmela De Santo, Issa Abu-Dayyeh, Sarah Booth,
Adrienne D. Cox, Kenneth P. Olive  Cancer Cell 
Cancer Immunotherapy by Dendritic Cells
Maša Alečković, Yibin Kang  Cancer Cell 
Antibody-modified T cells: CARs take the front seat for hematologic malignancies by Marcela V. Maus, Stephan A. Grupp, David L. Porter, and Carl H. June.
A proposed model of cross-talk among Helicobacter pylori, dendritic cells (DC), gastric epithelial cells and myeloid-derived suppressor cells (MDSC) leading.
Circulating blood dendritic cells from myeloid leukemia patients display quantitative and cytogenetic abnormalities as well as functional impairment by.
by Julia E. Geddings, and Nigel Mackman
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Markers of cancer cell and lymphocytes in inflammatory infiltration around a tumour as potential markers of immunomodulatory treatment response. Markers.
by Edward S. Morris, Kelli P. A. MacDonald, and Geoffrey R. Hill
by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle
by Emma Di Carlo, Guido Forni, PierLuigi Lollini, Mario P
Figure 4 Macrophage-targeting antitumour treatment approaches
Figure 1 A schematic representation of the role
Georges Makhoul, MD, MS, Ray C.J. Chiu, MD, PhD, Renzo Cecere, MD, MS 
Figure 2 Altered innate immune functions after sepsis
Laurence Zitvogel, Guido Kroemer  Cancer Cell 
Volume 24, Issue 5, Pages (November 2013)
Metabolic Reprogramming of Immune Cells in Cancer Progression
Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC
Mechanisms of immune escape in the tumor microenvironment.
Human MSC Suppression Correlates With Cytokine Induction of Indoleamine 2,3- Dioxygenase and Bystander M2 Macrophage Differentiation  Moïra François, Raphaëlle.
Host Immune Response to Infection and Cancer: Unexpected Commonalities
The Tim-3 pathway in cancer.
Turning Tumors into Vaccines: Co-opting the Innate Immune System
Juan R. Cubillos-Ruiz, Sarah E. Bettigole, Laurie H. Glimcher  Cell 
Figure 3 Tumours secrete factors that cause systemic immunosuppression
Mikala Egeblad, Elizabeth S. Nakasone, Zena Werb  Developmental Cell 
Learning from PD-1 Resistance: New Combination Strategies
Tumor-Associated Macrophages: From Mechanisms to Therapy
Adiponectin: an enlarging role in acute kidney injury
Jürgen C. Becker, David Schrama  Journal of Investigative Dermatology 
Nat. Rev. Urol. doi: /nrurol
The Dual Role of Bone Morphogenetic Proteins in Cancer
Nature immunology Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8+ T cells Huang Jie Wen.
Deciphering and Reversing Tumor Immune Suppression
David C. Soler, Thomas S. McCormick 
Characteristics and Significance of the Pre-metastatic Niche
Learning from PD-1 Resistance: New Combination Strategies
Mesenchymal Stromal Cells: Sensors and Switchers of Inflammation
Figure 4 Alemtuzumab-mediated effects on interleukin (IL)–23 and granulocyte-macrophage colony-stimulating factor (GM-CSF) production in innate myeloid.
Macrophage Classes and Roles in Immunity
Sundararaman Swaminathan, Matthew D. Griffin  Kidney International 
Plasmacytoid Dendritic Cells in Melanoma: Can We Revert Bad into Good?
Influence of the tumor microenvironment on FL
Clinical outcomes resulting from inhibition of tumor-intrinsic and myeloid NF-κB activation in melanoma chemotherapy. Clinical outcomes resulting from.
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Volume 17, Issue 2, Pages (February 2010)
Immune escape mechanisms in cancer.
Cancer-associated pathways and biomarkers of venous thrombosis
Graft Monocytic Myeloid-Derived Suppressor Cell Content Predicts the Risk of Acute Graft-versus-Host Disease after Allogeneic Transplantation of Granulocyte.
CD8+ depletion and IFN-γ–deficient myeloid cells and lung metastasis inhibition in Tgfbr2MyeKO mice. CD8+ depletion and IFN-γ–deficient myeloid cells and.
Immunological effects of anticancer therapy.
Development and function of MDSCs
Presentation transcript:

Cancer makes new friends with old tricks by Francesco Dazzi Blood Volume 122(7):1093-1094 August 15, 2013 ©2013 by American Society of Hematology

Tumor promotes the recruitment of myeloid- and mesenchymal-derived suppressor cells. Tumor promotes the recruitment of myeloid- and mesenchymal-derived suppressor cells. Tumor formation is associated with the recruitment of cells of myeloid and mesenchymal origin that, as a consequence of the tumor secretome, are polarized toward an antiinflammatory and immunosuppressive profile. Circulating fibrocytes detected in patients with metastatic tumor display features of the myeloid compartment and exert immunosuppressive activity in vitro. Because of these characteristics, fibrocytes can be affiliated to the group of MDSCs. The immunosuppressive activity can be attributed to the production of IDO, which depletes the cellular microenvironment of tryptophan, required for T-cell proliferation. Despite substantial differences in marker expression and lineage of origin, IDO is also the main mechanism by which tumor-polarized DCs or MSCs inhibit immune responses. In contrast, polarized monocytes, macrophages, and neutrophils preferentially use a different set of molecules including arginase, nitric oxide, interleukin (IL)-4, IL-10, and IL-13. Francesco Dazzi Blood 2013;122:1093-1094 ©2013 by American Society of Hematology